Osteoarthritis

Longitudinal stability of molecular endotypes of knee osteoarthritis patients

Osteoarthritis CartilagePublished Prospective cohort study

Authors' conclusion

Our study showed for the first time that more than half of KOA participants exhibited a longitudinally stable endotype

Study context

Population
Knee OA participants from the APPROACH cohort; independent knee OA population from the placebo arm of the oral salmon calcitonin trials226 with complete data
Participants
295 participants
Exposure
Structural damage vs Inflammation vs Low tissue turnover
Outcome
Longitudinal endotype stability (same independent endotype assignment longitudinally)
Follow-up
6, 12 and 24 months
Methodological detailslongitudinal, K-means clustering, external validation in placebo arm of oral salmon calcitonin trials, 19 biomarkers measured longitudinally
  • Longitudinal
  • K-means clustering
  • External validation in placebo arm of oral salmon calcitonin trials
  • 19 biomarkers measured longitudinally

Main finding

As reported in the abstract

Longitudinal endotype stability
GroupValueFleiss' Kappa
Structural damageaverage 59% (range 54–59%)0.52 (95% CI: 0.45, 0.60)
Inflammationaverage 54% (range 52–56%)0.61 (95% CI: 0.53, 0.68)
Low tissue turnoveraverage 50% (range 49–52%)0.46 (95% CI: 0.39, 0.54)

Value

Structural damageaverage 59% (range 54–59%)
Inflammationaverage 54% (range 52–56%)
Low tissue turnoveraverage 50% (range 49–52%)

Fleiss' Kappa

Structural damage0.52 (95% CI: 0.45, 0.60)
Inflammation0.61 (95% CI: 0.53, 0.68)
Low tissue turnover0.46 (95% CI: 0.39, 0.54)
Average overall longitudinal endotype stability
55%
Overall Fleiss' Kappa
0.53 (95% CI: 0.46, 0.60)

Observational data: associations, not effects.

Original publication

Longitudinal stability of molecular endotypes of knee osteoarthritis patients. Osteoarthritis Cartilage. Published 8 November 2024. doi:10.1016/j.joca.2024.11.002

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.